Tesaro prices Zejula

Tesaro Inc. (NASDAQ:TSRO) launched PARP inhibitor Zejula niraparib at a wholesale acquisition cost (WAC) of $9,833 per month, based on once-daily 200 mg daily dosing. The drug's label recommends a 300 mg daily dosage, which would cost $14,750 per month.

Spokesperson Jennifer Davis told BioCentury that 200 mg daily was the most commonly administered dose in Tesaro's Phase III NOVA study. She said about 69% of NOVA's patients reduced their Zejula dose from 300 mg, most within the first three cycles of treatment. The drug is sold in 100 mg capsules...